120 results match your criteria: "Diabetes Care Centre[Affiliation]"
Cureus
December 2024
Diabetes and Endocrinology, Prabhath Diabetes Care Centre, Udupi, IND.
This meta-analysis investigates the potential of allopurinol to prevent contrast-induced nephropathy (CIN), a common and serious complication of percutaneous coronary intervention (PCI). CIN is particularly prevalent among high-risk populations, including patients with chronic kidney disease (CKD) or acute coronary syndrome (ACS), where the administration of contrast agents can exacerbate renal injury. Allopurinol, a xanthine oxidase inhibitor, is known for its dual action in reducing oxidative stress and uric acid production, positioning it as a promising therapeutic candidate to mitigate CIN.
View Article and Find Full Text PDFIndian J Med Res
November 2024
Department of Diabetology, Madras Diabetes Research Foundation & Dr.Mohan's Diabetes Specialities Centre, Chennai, Tamil Nadu, India.
Background & objectives Biobanks are crucial for biomedical research, enabling new treatments and medical advancements. The biobank at the Madras Diabetes Research Foundation (MDRF) aims to gather, process, store, and distribute biospecimens to assist scientific studies. Methods This article details the profile of two cohorts: the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study and the Registry of people with diabetes in India with young age at onset (ICMR-YDR).
View Article and Find Full Text PDFJ Diabetes Metab Disord
June 2025
Department of Medicine, Gandhi Ward, King George's Medical University, Lucknow, India.
Purpose: Type 2 diabetes mellitus and hypertension frequently coexist, increasing the risk of cardiovascular and renal complications. Urinary Albumin Creatinine Ratio (UACR) serves as a crucial predictor of these outcomes. While renin-angiotensin system inhibitors are often initial therapy, evidence suggests a potential role for Azelnidipine, a non-dihydropyridine calcium channel blocker, in reducing UACR, especially in cases of persistent proteinuria despite optimal therapy.
View Article and Find Full Text PDFIndian J Endocrinol Metab
November 2024
Department of Genetics, MedGenome Labs, Tamil Nadu, India.
Introduction: Maturity-onset diabetes of the young (MODY) is a rare group of disorders characterised by impaired functions or development of pancreatic islets and monogenic diabetes at a young age. Diagnosing MODY can be rewarding for both clinicians and patients as it can change the management from generic to targeted therapy.
Methods: This study reports the retrospective analysis of data collected from four clinics between March 2016 and February 2023 from Lucknow, a city in northern India.
Sci Rep
October 2024
Department of Diabetology and Endocrinology, Lilavati Hospital and Research center, Mumbai, India.
This retrospective observational study, building on prior research that demonstrated the efficacy of the Digital Twin (DT) Precision Treatment Program over shorter follow-up periods, aimed to examine glycemic control and reduced anti-diabetic medication use after one-year in a DT commercial program. T2D patients enrolled had adequate hepatic and renal function and no recent cardiovascular events. DT intervention powered by artificial intelligence utilizes precision nutrition, activity, sleep, and deep breathing exercises.
View Article and Find Full Text PDFJ Assoc Physicians India
October 2024
Professor and Director, University of California, Irvine School of Medicine, Irvine, California, United States.
Adverse cardiovascular (CV) events have declined in Western countries due at least in part to aggressive risk factor control, including dyslipidemia management. The American and European (Western) dyslipidemia treatment guidelines have contributed significantly to the reduction in atherosclerotic cardiovascular disease (ASCVD) incidence in the respective populations. However, their direct extrapolation to Indian patients does not seem appropriate for the reasons described below.
View Article and Find Full Text PDFJ Assoc Physicians India
September 2024
Consultant Cardiologist, Medanta Moolchand Heart Centre, Delhi, India.
BMC Med Educ
September 2024
Vijayratna Diabetes Centre, Sumeru Centre, Paldi, Ahmedabad, India.
Background And Aim: Continuing Medical Education (CME) is crucial for physicians to stay current in the rapidly advancing field of medicine. A WhatsApp (WA) based community of physicians was initiated in 2016 'WhatsApp CME India Group' to facilitate learning, knowledge sharing, and discussion among physicians. Due to participant size constraints of the technology, it evolved into seven distinct WA groups, overseen by a central administrator.
View Article and Find Full Text PDFEur Heart J Suppl
June 2024
Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Raised blood pressure (BP) is the leading preventable risk factor for cardiovascular diseases that makes a major impact on early mortality and morbidity. Recognizing hypertension in the community, educating people about routine BP monitoring, and improving medication compliance are all important steps in detecting, controlling, and managing hypertension. During the course of 5 months, members of the Indian Society of Hypertension organized unique medical indoor and outdoor camps at 100 screening locations around India for the May Measurement Month (MMM) 2021 study.
View Article and Find Full Text PDFJ Assoc Physicians India
July 2024
Medical Affairs, Macleods Pharmaceuticals, Mumbai, Maharashtra, India.
Cureus
May 2024
Medical Affairs, Torrent Pharmaceuticals Ltd., Ahmedabad, IND.
Introduction Type 2 diabetes mellitus (T2DM), a prevalent chronic metabolic disorder, necessitates multifaceted treatment approaches. Emerging studies highlight the cardiovascular advantages of sodium-glucose transport protein 2 (SGLT2) and dipeptidyl peptidase 4 (DPP-4) inhibitors in T2DM. This investigation delves into the synergistic effects of the fixed-dose combination (FDC) of sitagliptin and dapagliflozin, offering insights into its safety and efficacy for the Indian population.
View Article and Find Full Text PDFJ Assoc Physicians India
May 2024
Consultant Cardiologist, Medanta Moolchand Heart Center, Delhi, India.
Chronic kidney disease (CKD) is a major contributor to morbidity and mortality in India. CKD often coexists with heart failure (HF), diabetes, and hypertension. All these comorbidities are risk factors for renal impairment.
View Article and Find Full Text PDFJ Assoc Physicians India
January 2024
Consultant Cardiologist, Medanta Moolchand Heart Center, Delhi, India.
J Assoc Physicians India
December 2023
Consultant Cardiologist, Medanta Moolchand Heart Center, Delhi, India.
Indian J Endocrinol Metab
February 2024
Internal Medicine, Harsh Clinic and Diabetes Care Centre, Lucknow, Uttar Pradesh, India.
Introduction: The study was aimed at identifying the incidence of unreported probable hypoglycaemia in individuals with type 2 diabetes (T2DM) on anti-diabetic medications, using the screening Stanford Hypoglycemia Questionnaire (SHQ) in real-world situations.
Methods: It was a multicentre cross-sectional study on consecutive individuals attending 10 diabetes care centres in Lucknow, Uttar Pradesh, India. The inclusion criteria were as follows: known individuals with T2DM, literate, age greater than or equal to 18 years, on at least one anti-diabetic agent for more than a month and not engaged in regular self-monitoring of blood glucose (SMBG).
Cureus
December 2023
Acute Medicine, Mid and South Essex NHS Foundation Trust, Southend on Sea, GBR.
Cardiac rehabilitation (CR) is a cost-effective intervention that can reduce cardiovascular disease (CVD) morbidity and mortality by 20%. Despite the clear benefits of CR, it remains unavailable and underutilized. This study aimed to assess the effectiveness of different CR models in reducing CVD-related morbidity and mortality in low-and middle-income countries.
View Article and Find Full Text PDFBlood Press Monit
December 2023
Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands.
Objective: The objective of this study is to identify 24-h blood pressure (BP) characteristics after acute stroke in Indian hospitalized patients.
Methods: In total, 769 patients [284 women (36.9%)] admitted at a hospital in South India were analyzed.
Diabetes Ther
December 2023
S K Diabetes Research and Education Centre, S V S Marwari Hospital Campus, Kolkata, India.
Introduction: Real-world evidence on insulin glargine 100 U/ml (Gla-100) initiation in Indian type 2 diabetes mellitus (T2DM) individuals is limited. The present study aimed to evaluate the effectiveness of Gla-100 in insulin-naïve T2DM participants from India.
Methods: This post hoc analysis includes real-world data of insulin-naïve Indian participants with T2DM who started Gla-100 treatment in two Asian registries: FINE ASIA and GOAL.
J Assoc Physicians India
February 2023
Consultant Endocrinologist, Pondicherry Institute of Medical Sciences, Puducherry, India.
People with type 2 diabetes mellitus (T2DM) have a higher risk of developing chronic liver disease (CLD) and its complications. T2DM, obesity, and insulin resistance are all strongly associated with nonalcoholic fatty liver disease (NAFLD). Conversely, people suffering from cirrhosis have reduced glucose tolerance in approximately 60% of cases, diabetes in 20% of cases, and insulin-mediated glucose clearance is lowered by 50% as compared with those who do not have cirrhosis.
View Article and Find Full Text PDFLancet Diabetes Endocrinol
July 2023
Department of Diabetology, Madras Diabetes Research Foundation and Dr Mohan's Diabetes Specialities Centre, Chennai, Tamil Nadu, India.
Background: Non-communicable disease (NCD) rates are rapidly increasing in India with wide regional variations. We aimed to quantify the prevalence of metabolic NCDs in India and analyse interstate and inter-regional variations.
Methods: The Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study, a cross-sectional population-based survey, assessed a representative sample of individuals aged 20 years and older drawn from urban and rural areas of 31 states, union territories, and the National Capital Territory of India.
Indian J Endocrinol Metab
November 2022
Consultant, Department of Endocrinologist, Pondicherry Institute of Medical Sciences, Kalapet, Puducherry, India.
Despite the availability of multiple therapeutic options and strategies, patients with type 2 diabetes mellitus (T2DM) the world over have inadequate glycaemic control and India is no exception. Patients with T2DM in India have benefitted from glucagon-like peptide-1 analogues similar to that of patients from other parts of the world. However, subcutaneous treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is limited by their injectable mode of administration.
View Article and Find Full Text PDFCureus
November 2022
Obstetrics and Gynecology, Institute of Obstetrics and Gynecology, Madras Medical College, Chennai, IND.
Diabetes mellitus in recent years has become a relentlessly evolving pandemic. Measures for the screening and early detection of diabetes are practiced all around the world. However, considering the ever-increasing magnitude of the problem, the present efforts should especially focus on the primordial prevention of diabetes.
View Article and Find Full Text PDFBMJ Open
November 2022
Department of Surgery and Cancer, Imperial College London, London, UK.
Introduction: Peripheral arterial disease (PAD) is a key risk factor for cardiovascular disease, foot ulceration and lower limb amputation in people with diabetes. Early diagnosis of PAD can enable optimisation of therapies to manage these risks. Its diagnosis is fundamental, though challenging in the context of diabetes.
View Article and Find Full Text PDFJ Assoc Physicians India
August 2022
Diabetologist, Sunil's Diabetes Care n' Research Centre, Nagpur, Maharashtra, India.
Background: The available evidence was systematically reviewed to evaluate the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) on cardiovascular (CV) and renal outcomes in people with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors (MRF), with or without heart failure (HF), and per estimated glomerular filtration rate (eGFR) rate at baseline.
Methods: We comprehensively searched three electronic databases to retrieve publications up to 30th November 2019, which were screened for inclusion. The data extracted for the outcomes according to baseline ASCVD, HF, and eGFR levels were meta-analyzed using fixed effects model.